Dynamic tests and basal values for defining active acromegaly

Neuroendocrinology

Volumn 83, Issue 3-4, 2006, Pages 200-204

  Tzanela, M ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Active acromegaly; Insulin like growth factor I; Oral glucose tolerance test; Somatotrope adenoma

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ACROMEGALY; AMENORRHEA; ARTHRALGIA; CLINICAL FEATURE; CONFERENCE PAPER; DIABETES MELLITUS; GALACTORRHEA; HEADACHE; HUMAN; HYPERTENSION; HYPOPHYSIS ADENOMA; IMPAIRED GLUCOSE TOLERANCE; IMPOTENCE; INCIDENCE; MORBIDITY; MORTALITY; NORMAL VALUE; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; PRIORITY JOURNAL; SWEATING; VISUAL IMPAIRMENT;

ACROMEGALY; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; REFERENCE VALUES;

EID: 33750079580     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095528     Document Type: Conference Paper

References (43)

1. Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B: Epidemiology and long-term survival in acromegaly: a study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 1980;223:327-335.
2. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M, on behalf of all the REA participants: Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry. Eur J Endocrinol 2004;151:439-446.
3. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A: The somatomedin hypothesis: 2001. Endocr Rev 2001;22:53-74.
4. Colao A, Ferone D, Marzullo P, Lombardi G: Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr Rev 2004;25:102-152.
5. Wright AD, Hill DM, Lowy C, Fraser TR: Mortality in acromegaly. Q J Med 1970;34:1-16.
6. Molitch ME: Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am 1992;21:597-614.
7. Bates AS, Van't Hoff W, Jones M, Clayton RN: An audit of outcome of treatment in acromegaly. Q J Med 1993;86:293-299.
8. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK: Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 1994;41:95-102.
9. Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT: Long term mortality after transphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419-3426.
10. Beauregard C, Truong U, Hardy J, Serri O: Long-term outcome and mortality after transphenoidal adenomectomy for acromegaly. Clin Endocrinol 2003;58:86-91.
11. Holdaway IM, Rajasoorya RC, Gamble GD: Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89:667-674.
12. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki M, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman U, Viikari J, Voutilainen E: A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 2005;90:4081-4086.
13. Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Scutte PJ, van Dulken H, Romijin JA, Roelfsema F: Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 2004;89:2789-2796.
14. Ladas SD, Thalassinos NC, Ioannides G, Raptis SA: Does acromegaly really predispose to an increased prevalence of gastrointestinal tumours? Clin Endocrinol (Oxf) 1994;41:597-601.
15. Jenkins PJ, Fairclough PD: Colorectal neoplasia in acromegaly. Clin Endocrinol (Oxf) 2001;55:727-729.
16. Melmed S: Acromegaly and cancer: not a problem. J Clin Endocrinol Metab 2001;86:2929-2934.
17. Muller E, Locatelli V, Cocchi D: Neuroendocrine control of growth hormone secretion. Physiol Rev 1999;79:511-608.
18. Duncan E, Wass JAH: Investigation protocol: acromegaly and its investigation. Clin Endocrinol 1999;50:285-293.
19. Guistina A, Barkan A, Casanueva F, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Wender K, Melmed S: Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85:526-529.
20. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood L: Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 1979;301:1138-1142.
21. Barkan AL, Beitins IZ, Kelch RP: Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab 1988;67:69-73.
22. Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the growth hormone research society and the pituitary society. J Clin Endocrinol Metab 2004;89:3099-3102.
23. Peacey SR, Toogood AA, Veldhuis JD, Thorner MO, Shalet SM: The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy. J Clin Endocrinol Metab 2001;86:259-266.
24. Biermasz NR, van Dulken H, Roelfsema F: Ten-year follow-up results of transphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab 2000;85:4596-4602.
25. Kaltsas GA, Isidori AM, Florakis D: Predictors of outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J Clin Endocrinol Metab 2001;86:1645-1652.
26. Shalet SM: Biochemical monitoring of disease activity after surgery for acromegaly. J Clin Endocrinol Metab 2004;89:492-494.
27. Holly JM, Cotterill AM, Jemmott RC: Interrelations between growth hormone, insulin, insulin-like growth factor-I (IGF-I), IGF-binding protein-1 (IGFBP-1) and sex hormone binding globulin in acromegaly. Clin Endocrinol 1991;34:275-280.
28. Costa ACF, Rossi A, Martinelli C, Machado HR, Moreira AC: Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab 2002;87:3142-3147.
29. Vierhapper H, Heinze G, Gessl A, Exner M, Bieglmayr C: Use of the oral glucose tolerance test to define remission in acromegaly. Metabolism 2003;52:181-185.
30. Freda PU, Post KD, Powell JS, Wardlaw SL: Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998;83:3808-3816.
31. Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD: Significance of 'abnormal' nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels? J Clin Endocrinol Metab 2004;89:495-500.
32. Puder J, Nilavar S, Post K, Freda F: Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab 2005;90:1972-1978.
33. Orne SM, McNally RJ, Cartwright RA, Belchetz PE: Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1988;83:2730-2734.
34. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB: Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 1998;83:3411-3418.
35. Serri O, Beauregard C, Hardy J: Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. J Clin Endocrinol Metab 2004;89:658-661.
36. Feelders RA, Bidlingmaier M, Strasburger CJ, Janssen AMJL, Uitterlinden P, Hofland LJ, Lamberts SWJ, van der Lely AJ, de Herder WW: Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. J Clin Endocrinol Metab 2005;90:6480-6489.
37. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Von Werder K, Wass J, Guistina A: Guidelines for acromegaly management. J Clin Endocrinol Metab 2002;87:4054-4058.
38. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ: Treatment of acromegaly with the growth hormone receptor antagonist pegvisomant. N Engl J Med 2000;342:1171-1177.
39. Clemmons DR, Chihara K, Freda P, et al: Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab 2003;88:4759-4767.
40. Muller AF, Kopchick JJ, Flyvbjerg A, van der Lely AJ: Growth hormone receptor antagonists. J Clin Endocrinol Metab 2004;89:1503-1511.
41. Marzullo P, Di Somma C, Pratt K, Khosravi J, Diamandis A, Lombardi G, Colao A, Rosenfield RG: Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults. J Clin Endocrinol Metab 2001;86:3001-3008.
42. Arosio M, Garrone S, Bruzzi P, Faglia G, Minuto F, Barreca A: Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2 and -3. J Clin Endocrinol Metab 2001;86:1091-1098.
43. Tzanela M, Christoforaki M, Papastathopoulou L, Vassiliadi D, Botoula E, Trivizas P, Thalassinos N: Growth hormone binding protein and acid labile subunit levels in the assessment of acromegaly treatment. Hormones 2005;1:148-151.